


FORM PTO 1449	ATTY. DOCKET NO. 0273-0007	APPLICATION NO. 10/026,931
INFORMATION DISCLOSURE STATEMENT	APPLICANT(S) Mahler et al	
	FILING DATE December 27, 2001	GROUP 1614



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

PN	A		Hage-Hamsten, M. et al, <i>Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: Results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season</i> , <i>J. Allergy Clin. Immunol.</i> , 104:969-77 (1999)
	B		Hoffman-Sommergruber, K. et al, <i>High-Level Expression and Purification of the Major Birch Pollen Allergen, Bet v 1, Protein Expression and Purification</i> , 9: 33-9 (1997)
	C		Kazemi-Shirazi, L. et al, <i>Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy</i> , <i>J. Allergy Clin. Immunol.</i> , 105: 116-25, (2000)
	D		Lee, W. et al., <i>Abrogation of reaginic antibodies with modified allergens</i> , <i>Nature</i> , 267: 618-19 (1977)
	E		Lowry, O. et al, <i>Protein Measurement with the Folin Phenol Reagent</i> , <i>J. Biol. Chem.</i> , 193: 265-75 (1951)
	F		Marsh, D. et al, <i>Studies on 'Allergoids' Prepared from Naturally Occurring Allergens</i> , <i>Immunology</i> , 18: 705-22 (1970)
	G		Møllerup, M. et al, <i>Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment</i> , <i>Clinical and Experimental Allergy</i> , 30: 1423-29 (2000)
	H		Metzger, W. et al, <i>Clinical and immunologic evaluation of glutaraldehyde-modified, tyrosine-absorbed short ragweed extract: a double-blind, placebo-controlled trial</i> , <i>J. Allergy Clin. Immunol.</i> , 68(6): 442-48 (1981)
	I		Niederberger, V. et al., <i>Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: A quantitative IgE inhibition study with sera from different populations</i> , <i>J Allergy Clin. Immunol.</i> , 102: 579-91 (1998)
	J		Pauli, G. et al, <i>Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population</i> , <i>Clinical and Experimental Allergy</i> , 30: 1076-84 (2000)
	K		Vrtala S. et al, <i>Conversion of the Major Birch Pollen Allergen, Bet v 1, into Two Nonanaphylactic T Cell Epitope-containing Fragments</i> , <i>J. Clin. Invest.</i> 99(7): 1673-81 (1997)
PN	L		Vrtala S. et al, <i>Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy</i> , <i>Int. Arch. Allergy Immunol.</i> , 118:218-19 (1999)

EXAMINER <i>Pat L. Nor</i>	DATE CONSIDERED <i>9/29/04</i>
-------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED
JUN 07 2002
TECH CENTER 1600/2900